{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:09:53Z","timestamp":1791104993598,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s10637-005-2908-y","type":"journal-article","created":{"date-parts":[[2005,8,13]],"date-time":"2005-08-13T20:13:36Z","timestamp":1123964016000},"page":"485-487","source":"Crossref","is-referenced-by-count":131,"title":["A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study"],"prefix":"10.1007","volume":"23","author":[{"given":"John S.","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syma","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James L.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K.","family":"Giguere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"2908_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","volume":"52","author":"A Jemal","year":"2002","unstructured":"Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 52: 23\u201347, 2002.","journal-title":"CA Cancer J Clin"},{"key":"2908_CR2","first-page":"220","volume":"23","author":"SF Schnall","year":"1996","unstructured":"Schnall, SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220\u2013228, 1996.","journal-title":"Semin Oncol"},{"key":"2908_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00000658-199709000-00004","volume":"226","author":"CJ Yeo","year":"1997","unstructured":"Yeo CJ, Cameron JL, Sohn TA: Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226: 248\u2013257, 1997.","journal-title":"Ann Surg"},{"key":"2908_CR4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson F, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15: 2403\u20132413, 1997.","journal-title":"J Clin Oncol"},{"key":"2908_CR5","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61: 131\u2013137, 2001.","journal-title":"Cancer Res"},{"key":"2908_CR6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ijc.2910430614","volume":"43","author":"K Gr\u00fcnewald","year":"1989","unstructured":"Gr\u00fcnewald K, Lyons J, Fr\u00f6hlich A: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43: 1037\u20131041, 1989.","journal-title":"Int J Cancer"},{"issue":"7","key":"2908_CR7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2003.08.040","volume":"21","author":"SJ Cohen","year":"2003","unstructured":"Cohen SJ, Linus H, Sulabha R, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21(7): 1301\u20131306, 2003.","journal-title":"J Clin Oncol"},{"key":"2908_CR8","unstructured":"Van Custem E, Karasek P, Oettle H, Vervenne W, Szawlowski A, Schoffski P, Post S, Neumann H, Safran H, Humblet Y, van de Velde H, Ma Y, Von Hoffl: Phase III trial comparing gemcitabine +R11577 (Zarnestra) versus gemcitabine +placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21: 130a, 2002 (abstr 21)."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-2908-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-005-2908-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-2908-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-2908-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:03:00Z","timestamp":1678557780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-005-2908-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["2908"],"URL":"https:\/\/doi.org\/10.1007\/s10637-005-2908-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}